Intracoronary Abciximab or Aspiration Thrombectomy During Primary PCI?

Abciximab reduced infarct size, whereas aspiration thrombectomy did not; however, the effect was small and highly restricted.

Previous studies of the adjunctive use of glycoprotein IIb/IIIa platelet inhibitors or catheter thombectomy during primary percutaneous coronary intervention (PCI) for ST-segment-elevation myocardial infarction (MI) have produced conflicting results. In this randomized, 2×2 factorial study, researchers compared bolus-only intracoronary abciximab (0.25 mg/kg), delivered into the thrombus region with an infusion catheter, and manual aspiration thrombectomy with the Export catheter in patients undergoing primary PCI with bivalirudin anticoagulation. The trial was funded by both catheter manufacturers.

Eligible patients had anterior MI and presented within 4 hours after symptom onset. Patients also had to have a proximal or mid-left anterior des…

Reviewing Author

Howard C. Herrmann, MD

Disclosures

Consultant/Advisory BoardAffluent Medical; Artedrone; Caranx; Johnson & Johnson; Medtronic; Prolifagen; Wells Fargo

EquityMicrointerventional Devices, Inc.

RoyaltiesUniversity of Pennsylvania

Grant/Research SupportAbbott Vascular; Edwards Lifesciences; Johnson & Johnson; Medtronic

Editorial BoardsCatheterization and Cardiovascular Interventions; Journal of the American College of Cardiology; Circulation: Cardiovascular Interventions; JACC Cardiovascular Interventions; JACC Case Reports; JSCAI